The fund was founded by three alums of Lux Capital and Obvious Ventures. Dimension will target early state companies specializing in drug discovery platforms, machine learning and software companies in the life sciences field, according to a Jan. 25 Dimension letter to investors.
Addressing questions of economic uncertainty, Dimension said it believes that the “long-term potential of technology and science is independent from market cycles.”
“A generational confluence of advances in software, hardware, machine learning and lab science have created prime conditions for a leap forward in life science capability and productivity,” Dimension said in the letter to investors. “The digitization of life sciences will transform the entire end-to-end journey of medicines.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.